GlassScriptPhysician profile
Maan Khatib
NPI 1750648804
$1,020.93
in general payments reported to CMS, 2019-2025
19 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $30.97 · 2021: $86.43 · 2022: $320 · 2023: $217 · 2024: $86.13 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $151.87 | 2019-2023 | Kristalose |
| Globus Medical, INC. | $132.82 | 2025 | Senza |
| Nestle Healthcare Nutrition INC. | $111.36 | 2022-2023 | |
| Abbvie INC. | $101.48 | 2019-2023 | Creon |
| Regeneron Healthcare Solutions, INC. | $99.03 | 2022-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $79.59 | 2021-2024 | Gattex |
| Qol Medical, LLC | $54.08 | 2022-2023 | Sucraid |
| Pharming Healthcare, INC. | $45.40 | 2022-2023 | Ruconest |
| Novartis Pharmaceuticals Corporation | $32.55 | 2019 | |
| Acadia Pharmaceuticals INC | $32.48 | 2024 | Daybue |
| Alcresta Therapeutics, INC. | $32.09 | 2022 | |
| Ptc Therapeutics, INC. | $24.17 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.55 | 2023 | Ultomiris |
| Travere Therapeutics, INC. | $19.24 | 2019 | |
| Sarepta Therapeutics, INC. | $18.92 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $18.73 | 2021 | |
| Sandoz INC. | $16.67 | 2023 | Hyrimoz |
| Mirum Pharmaceuticals, INC. | $14.88 | 2023 | Livmarli |
| Albireo Pharma, INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maan Khatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.